Abstract

IN-VITRO AND IN-VIVO EVALUATION OF DIRECTLY COMPRESSED TABLETS OF SIMVASTATIN WITH SOY LECITHIN

*Ugandar R E, Kiran C Nilugal and Lui Dee Lyn

Abstract

The study was conducted to carry out comparative in-vitro evaluation of two different formulations of Simvastatin tablets containing Soy lecithin (F2) and MCC (F3) to evaluate Soy Lecithin as a direct compression vehicle and a comparative in-vivo evaluation to observe potential anti-cholesterol activity with the Soy Lecithin and Simvastatin combination tablets (F2). A blank formulation of tablet was formulated which was F1 containing Soy Lecithin alone. The formulations were subjected to in-vitro evaluation. The formulation blends were subjected to pre compression studies and were found to exhibit good flow properties. All the three formulation blends were formulated into tablets by means of direct compression. Magnesium Stearate was added as a lubricant in F3. The prepared tablets of F1, F2 and F3 were subjected to post compression. The results revealed good post compression properties and F2 tablets have shown better release of Simvastatin during dissolution rate study. The study revealed that soy lecithin could function as a substitute DCV in directly compressed tablets. In the invivo studies, the three formulations of tablets were administered against fructose-induced hyperlipidemic in rats. The results of treated animals have revealed that there was significant decrease respectively in the levels of serum total cholesterol, LDL cholesterol and significant increase in HDL cholesterol in serum when compared to the induced control group. Rats administered with F2 tablets shown the maximum reduction in total cholesterol and LDL Cholesterol and highest elevation in HDL cholesterol. This proved that Soy Lecithin in combination with Simvastatin possesses potential cholesterol lowering effect.

Keywords: Simvastatin, Soy Lecithin, MCC, Direct Compression Vehicle, Potential Cholesterol Lowering agent.